The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
As enologists began better understanding the science of fermentation, nitrogen was identified as a principal nutrient and winemakers as early as the 1900s began adding ammonium salts to their must. Urea was also used as an early nitrogen supplement but research linking it to the development of ethyl carbamate has led to its banning in many countries, including the United States since 1990. There are many types of nitrogen supplements available for winemakers to use. Most of them are complex formulations that include nitrogen (from either amino acids or ammonium salts) along with vitamins, minerals and other growth factors and sold under brand names like Go-Ferm, Superfood, Fermaid K (the later two also containing some DAP). Amino acids can be added directly to the must though as of 2010 only glycine is permitted to be added to must in the United States.
Although theoretically a consensus-building collegial body, Gaddafi dominated the RCC. Some of the others attempted to constrain what they saw as his excesses. Gaddafi remained the government's public face, with the identities of the other RCC members only publicly revealed on 10 January 1970. All were young men from lower-class backgrounds without university degrees, which distinguished them from the wealthy, educated conservatives who previously governed the country. The coup completed, the RCC proceeded with consolidating power and modernizing the country. They purged monarchists and members of Idris' Senussi clan from Libya's political world and armed forces; Gaddafi believed them opposed to the will of the Libyan people. People's Courts were founded to try various monarchist politicians and journalists, many of whom were imprisoned, although none executed. Idris was sentenced to execution in absentia. Three months after Gaddafi came to power, the army minister and interior minister, both from the eastern Barqa region, tried to overthrow him in a failed coup. In 1970, Idris' great-nephew Ahmed al-Senussi attempted another coup against Gaddafi; the monarchist plot was foiled in August and Ahmed was sentenced to death (commuted in 1988 and pardoned by Gaddafi in 2001). In May 1970, the Revolutionary Intellectuals Seminar was held to bring intellectuals in line with the revolution, while that year's Legislative Review and Amendment introduced sharia into the legal system.
Mahmoud Reza Banki (Persian: محمودرضا بانکی; born 1976) is an Iranian-American scientist, management consultant and business executive. Born in Tehran, Iran, Banki immigrated to the US to attend college and became a naturalized US citizen in the 1990s. In January 2010, Banki was arrested and charged with violating US sanctions against Iran by the United States Attorney's office in New York City. Ultimately Banki won his case on appeal, and it was permanently closed in July 2012. Banki spoke about his case at a TED Talk in 2014, presenting a case for change in criminal justice. As of 2015 a documentary film about the case was being made. In The Moth podcast released January 2017, Banki spoke to the personal toll of the ordeal. Banki has also spoken before various audiences for the cause of improving the criminal justice system. As of 2022, Banki was Chief Financial Officer and Chief Strategy Officer at leading streaming company Tubi. On January 20, 2021, Banki received a full and unconditional pardon from the President of the United States. He was the CFO of X Corp. between November 2024 and October 2025.
In a clandestine setting, DMT is not typically synthesized due to the lack of availability of the starting materials, namely tryptamine and oxalyl chloride. Instead, it is more often extracted from plant-sources using a nonpolar hydrocarbon solvent such as naphtha or heptane, and a base such as sodium hydroxide. Alternatively, an acid-base extraction is sometimes used instead. A variety of plants contain DMT at sufficient levels for being viable sources such as Mimosa tenuiflora, Acacia acuminata, Acacia confusa, Acacia maidenii, Arundo donax, 'Diplopterys cabrerana, Psychotria viridis. The chemicals involved in the extraction are commonly available. The plant-material may be illegal to procure in some countries. The end-product (DMT) is illegal in most countries.
In molecular biology, initiation factors are proteins that bind to the small subunit of the ribosome during the initiation of translation, a part of protein biosynthesis. Initiation factors can interact with repressors to slow down or prevent translation. They have the ability to interact with activators to help them start or increase the rate of translation. In bacteria, they are simply called IFs (i.e.., IF1, IF2, & IF3) and in eukaryotes they are known as eIFs (i.e.., eIF1, eIF2, eIF3). Translation initiation is sometimes described as three step process which initiation factors help to carry out. First, the tRNA carrying a methionine amino acid binds to the small subunit of ribosome, then binds to the mRNA, and finally joins together with the large subunit of ribosome. The initiation factors that help with this process each have different roles and structures.
Sources: en.wikipedia.org
The provision of the law allowed the president to determine what constitutes "torture". On March 8, 2008, Bush vetoed H.R. 2082, a bill that would have expanded congressional oversight over the intelligence community and banned the use of waterboarding as well as other forms of interrogation not permitted under the United States Army Field Manual on Human Intelligence Collector Operations, saying that "the bill Congress sent me would take away one of the most valuable tools in the War on Terror". In April 2009, the ACLU sued and won release of the secret memos that had authorized the Bush administration's interrogation tactics. One memo detailed specific interrogation tactics including a footnote that described waterboarding as torture and stated that the form of waterboarding used by the CIA was far more intense than authorized by the Justice Department.
=== Pre-history: the helical structure of RNA === The earliest work in RNA structural biology coincided, more or less, with the work being done on DNA in the early 1950s. In their seminal 1953 paper, Watson and Crick suggested that van der Waals crowding by the 2`OH group of ribose would preclude RNA from adopting a double helical structure identical to the model they proposed—what we now know as B-form DNA. This provoked questions about the three-dimensional structure of RNA: could this molecule form some type of helical structure, and if so, how? As with DNA, early structural work on RNA centered around isolation of native RNA polymers for fiber diffraction analysis. In part because of heterogeneity of the samples tested, early fiber diffraction patterns were usually ambiguous and not readily interpretable. In 1955, Marianne Grunberg-Manago and colleagues published a paper describing the enzyme polynucleotide phosphorylase, which cleaved a phosphate group from nucleotide diphosphates to catalyze their polymerization. This discovery allowed researchers to synthesize homogenous nucleotide polymers, which they then combined to produce double stranded molecules. These samples yielded the most readily interpretable fiber diffraction patterns yet obtained, suggesting an ordered, helical structure for cognate, double stranded RNA that differed from that observed in DNA. These results paved the way for a series of investigations into the various properties and propensities of RNA.
== Management == Early diagnosis and treatment can reduce the incidence of complications such as cataracts and neuropathy. Since dogs are insulin dependent, oral diabetes drugs, which require a functional endocrine pancreas with beta cells capable of producing insulin, are ineffective. Diabetic dogs require insulin therapy, which must be continued for life. The goal of treatment is to regulate blood glucose using insulin and some probable diet and daily routine changes. The process may take a few weeks or many months and is similar as in type 1 diabetic humans. The aim is to keep the blood glucose values in an acceptable range. The commonly recommended dosing method is by "starting low and going slow" as indicated for people with diabetes. During the initial process of regulation and periodically thereafter, the effectiveness of the insulin dose at controlling blood glucose is evaluated. This is done by a series of blood glucose tests called a curve. Blood samples are taken and tested at intervals of one to two hours over a 12- or 24-hour period. The results are generally transferred into graph form for easier interpretation. They are compared against the feeding and insulin injection times for judgment. The curve provides information regarding the action of the insulin in the animal.
=== Hospitals === The Assistance Publique–Hôpitaux de Paris (AP-HP) preserves numerous archives, some dating back to the Middle Ages. The oldest hospitalization registers—approximately one million pages—have been digitized and made available online. “Population registers” document admissions, discharges, births, and deaths. Each hospital maintains two types of annual records: alphabetical indexes to locate individuals and chronological registers specifying civil status, reasons for admission, and, in some cases, causes of death.
=== Covalent catalysis === Many enzymes including serine protease, cysteine protease, protein kinase and phosphatase evolved to form transient covalent bonds between them and their substrates to lower the activation energy and allow the reaction to occur. This process can be divided into 2 steps: formation and breakdown. The former step is rate-limit step while the later step is needed to regenerate intact enzyme. Nucleophilic catalysis: This process involves the donation of electrons from the enzyme's nucleophile to a substrate to form a covalent bond between them during the transition state. The strength of this interaction depends on two aspects.: the ability of the nucleophilic group to donate electrons and the electrophile to accept them. The former one is mainly affected by the basicity(the ability to donate electron pairs) of the species while the later one is in regard to its pKa. Both groups are also affected by their chemical properties such as polarizability, electronegativity and ionization potential. Amino acids that can form nucleophile including serine, cysteine, aspartate and glutamine. Electrophilic catalysis: The mechanism behind this process is exactly same as nucleophilic catalysis except that now amino acids in active site act as electrophile while substrates are nucleophiles. This reaction usually requires cofactors as the amino acid side chains are not strong enough in attracting electrons.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.